Olema Pharmaceuticals Inc (OLMA) Stock Forecast & Price Target
Olema Pharmaceuticals Inc · NASDAQ
$12.00+0.30 (+2.56%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Olema Pharmaceuticals Inc, 10 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $35.00 to $40.00, so the covering firms are broadly aligned. The average target of $37.50 sits 213% above the current $12.00. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.58 next quarter toward $-2.48 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Moderate Buy
Strong Buy00%
Buy1091%
Hold19%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Olema Pharmaceuticals Inc.
As of Jul, 10 of 11 firms rate OLMA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
OLMA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.58
Range $-0.69 – $-0.47 · 9 analysts · +18% YoY
Next period, 9 analysts expect Olema Pharmaceuticals Inc to earn $-0.58 a share (range $-0.69 – $-0.47), versus $-0.49 a year earlier. Full-year consensus is $-2.27, growing to $-2.48 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 9 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $23.1M next year.
Top analysts covering Olema Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OLMA.
#1
Anupam Rama
JP Morgan · Rank #62
Buy
$52.00+333.3% to target
Overall win rate
46%
+ Follow
#2
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$62.00+416.7% to target
Overall win rate
43%
+ Follow
#3
Emily Bodnar
HC Wainwright & Co. · Rank #338
Buy
$38.00+216.7% to target
Overall win rate
22%
+ Follow
#4
Bradley Canino
Guggenheim
Buy
$35.00+191.7% to target
Coverage
—
+ Follow
#5
KP
Kalpit Patel
Wolfe Research
Hold
No targeton OLMA
Coverage
—
+ Follow
OLMA stock forecast FAQ
What is OLMA's average 12-month price target?+
The 2 analysts with a live target average $37.50 for Olema Pharmaceuticals Inc over the next 12 months, ranging from a $40.00 high to a $35.00 low.
Is OLMA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 11 analyst ratings, 10 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for OLMA?+
The Street-high target is $40.00 (Jefferies), and the Street-low is $35.00 (Guggenheim). The average of all 2 active targets is $37.50.
How many Wall Street analysts cover OLMA?+
11 analysts have an active rating on Olema Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering OLMA?+
Among analysts who currently cover OLMA, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #62). Their current call is Buy with a $52.00 target.
What is Olema Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.58 per share (range $-0.69 – $-0.47) across 9 analysts. Full-year EPS is projected at $-2.27, rising to $-2.48 the following year.
How much revenue is Olema Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $23.1M next year.
Have analysts been upgrading or downgrading OLMA lately?+
As of Jul, 10 of 11 firms rate OLMA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OLMA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
